推荐产品
生化／生理作用
Proteasomes are responsible for the cleavage of peptides in an ATP/ubiquitin-dependent manner.
VR23 is a potent inhibitor of proteasome that primary targets β2 of the 20S proteasome catalytic subunit. VR23 selectively induces apoptosis to cancer cells via cyclin E–mediated centrosome amplification. VR23 exhibit little effect on noncancerous cells.
訊號詞
Warning
危險聲明
危險分類
Acute Tox. 4 Oral
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
Sheetal Pundir et al.
Cancer research, 75(19), 4164-4175 (2015-08-05)
The proteasome is clinically validated as a target for cancer therapeutics. However, proteasome-inhibitory agents that are cancer selective have yet to be developed. In this study, we report the identification of a safe and effective proteasome inhibitor with selective anticancer
G Munkácsy et al.
British journal of cancer, 102(2), 361-368 (2009-12-17)
To date individual markers have failed to correctly predict resistance against anticancer agents in breast cancer. We used gene expression patterns attributable to chemotherapy-resistant cells to detect potential new biomarkers related to anthracycline resistance. One of the genes, PSMB7, was
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门